Charles Lester, MD
Psychiatry · Muskogee, OKNPI 1851357974
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,649 of the $38,960 with a category attached, or 88.9%. 21 manufacturers reported payments, led by AbbVie at 46.5% of the total. Reporting peaked in 2021 at $17,154 and has fallen 99.2% since, to $143 in 2025. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $179.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$18K
- Supernus Pharmaceuticals, Inc.$10K
- Sunovion Pharmaceuticals Inc.$9K
- Teva Pharmaceuticals USA, Inc.$442
- Otsuka America Pharmaceutical, Inc.$352
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$340
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$34,64989%
- Travel & lodging$1,1943%
- Food & beverage$2,8277%
- Education$2901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $18,122 |
| Supernus Pharmaceuticals, Inc. | 29 | $9,785 |
| Sunovion Pharmaceuticals Inc. | 12 | $8,903 |
| Teva Pharmaceuticals USA, Inc. | 4 | $442 |
| Otsuka America Pharmaceutical, Inc. | 18 | $352 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $340 |
| Vanda Pharmaceuticals Inc. | 20 | $291 |
| Axsome Therapeutics, Inc. | 8 | $225 |
| Alkermes, Inc. | 11 | $166 |
| Lundbeck LLC | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Merck | 2 | $30 |
| Johnson & Johnson | 2 | $26 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Biogen | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,960 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 21 | $316,728 |
| VraylarCariprazine Hcl | 65 | $99,236 |
| AuvelityDextromethorphan Hbr/Bupropion | 56 | $65,427 |
| FanaptIloperidone | 16 | $53,104 |
| RexultiBrexpiprazole | 20 | $38,970 |
| BelsomraSuvorexant | 81 | $35,095 |
| LybalviOlanzapine/Samidorphan Malate | 21 | $34,486 |
| Abilify MaintenaAripiprazole | 12 | $30,409 |
| TrintellixVortioxetine Hydrobromide | 49 | $26,662 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $20,571 |
| Aripiprazole | 188 | $15,141 |
| FetzimaLevomilnacipran Hcl | 20 | $13,881 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 190 | $7,412 |
| CymbaltaDuloxetine Hcl | 11 | $6,231 |
| Quetiapine Fumarate | 290 | $5,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $442 | $316,72821 claims |
| AbbVieVraylar, Fetzima, Viibryd | $18,122 | $116,87596 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $352 | $69,37932 claims |
| Axsome Therapeutics, Inc.Auvelity | $225 | $65,42756 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $291 | $53,10416 claims |
| MerckBelsomra | $30 | $35,09581 claims |
| Alkermes, Inc.Lybalvi | $166 | $34,48621 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $43 | $31,50062 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $25 | $20,57113 claims |
| Eisai Inc.Dayvigo | $18 | $5,33115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Muskogee
- Robert MortonAda$1.9M
- Sarah LandTulsa$287K
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Jennifer MorrisEdmond$26K
- Julia IrwinNorman$16K
- Bradley McClureTulsa$15K
- Richard HartmanNorman$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.